En esta página
01NKTR precio
02Instantánea
03Gráfico
04Divisiones de acciones
05Acerca de
06Rendimiento
07Valoración y ratios
14Ganancias
15Fundamentales Completos
16Estados Financieros
17Propietarios institucionales (13F)
18Activistas y propietarios del %+ 5
19Informantes de la empresa
20Propiedad de ETFs
21Consenso
22Pares
23Noticias
26Mis Métricas
NKTR Nektar Therapeutics - Common Stock
NASDAQ · Pharmaceuticals · Ver en SEC EDGAR ↗ cerrar Oct 2, 2026 10-K/10-Q Ago 14, 2026
$43,58
· % del rango de 52 semanas
· por encima del mínimo
· a alto
$33,40mínimo 52 semanas
$109,00máximo 52 semanas
Capitalización Bursátil (MRQ)
$888M
P/E (TTM)
-4.5
BPA (TTM)
$-9.59
Ingresos (TTM)
$55M
tus insignias
Rango 52S
$33–$109
Calificación del Analista
BUY
Precio Objetivo
$141
P/E
-4.5
ROE
-35.8%
Margen de Beneficio Neto
-287.8%
Tu barra de insignias está vacía — fija una métrica en cualquier lugar de esta página.
NKTR Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$43.58
Capitalización Bursátil (MRQ)
$888M
P/E (TTM)
-4.5
BPA (TTM)
$-9.59
Ingresos (TTM)
$55M
ROE (TTM)
-35.8%
Rango 52S
$33–$109
NKTR Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
rango
barras
La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.
Divisiones de acciones
| Fecha ex-dividendo | División | Tipo |
|---|---|---|
| 9 de junio de 2025 | 1-for-15 | Inversa |
| 23 de agosto de 2000 | 2-for-1 | Adelante |
Acerca de Nektar Therapeutics - Common Stock Descripción general de la empresa de Wikipedia
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.
Background
The company is engaged in developing a proprietary pipeline of drug candidates for several therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. The company's research and development involve in small molecule and biologic drug candidates. Its drug candidate base consists of naloxegol (Movantik), a Phase III oral opioid antagonist, etirinotecan pegol, a topoisomerase inhibitor under Phase III clinical study as of 2012, NKTR 061, NKTR-181, NKTR-214, etc.
In 2013, the company was assigned a patent which was developed by the company and other four co-inventors. The products of the company is served as a supplement to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability and other areas of drugs for the patients worldwide. As of March 2014, the company had a market capitalization of $1.7 billion with an enterprise value of $1.67 billion.
As of December 2024, at a stock price-per-share of roughly $1, the market cap is roughly $171 million. Nektar underwent periods of downsizing after unsuccessful partnerships were ended with Eli Lilly in 2023 and Bristol Myers Squibb in 2022, resulting in layoffs of most company employees.
Pipeline
Etirinotecan pegol was in the phase III BEACON trial as well as in the I-SPY2 adaptive clinical trial for breast cancer in 2016. The European Medicines Agency refused a marketing authorisation in 2017.
Bempegaldesleukin (NKTR-214) is a CD122-biased immune-stimulatory cytokine, Phase I results were announced in November 2016. It is now in a phase 2 trial in combination with nivolumab for various advanced cancers.
In 2023 Nektar's partnership with Eli Lilly in development of "rezpeg" was ended. Eli Lilly claimed the drug lacked suitable efficacy, while Nektar responded that Eli Lilly had botched the analysis.
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
sectorHealthcare
industriaPharmaceuticals
empleados63
paísUS
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos$55M2016-12-31 → 2025-12-31
BPA$-9.732016-12-31 → 2025-12-31
Flujo de caja libre$-209M2016-12-31 → 2025-12-31
Margen neto-287.8%2016-12-31 → 2025-12-31
Valoración y ratios
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
| Métrica | Tendencia a 5 años | NKTR | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| P/E (TTM) | -4.5promedio 5A ≈-20.0 | ≈-20.0 | · | · | |
| P/S (TTM) | 16.3promedio 5A ≈99.6 | ≈99.6 | 4.5 | Sobrevalorado | |
| P/C (MRQ) | 1.0promedio 5A ≈27.5 | ≈27.5 | 7.2 | Infravalorado | |
| Precio / FCF (TTM) | -3.8promedio 5A ≈-27.1 | ≈-27.1 | · | · | |
| Precio / Flujo de Caja (TTM) | -3.8promedio 5A ≈-27.9 | ≈-27.9 | · | · | |
| Price / Tangible Book (Precio / Valor Contable Tangible) | 14.3promedio 5A ≈29.8 | ≈29.8 | · | · |
La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
| Métrica | Tendencia a 5 años | NKTR | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Margen Operativo (TTM) | -257.8%promedio 5A ≈-299.9% | ≈-299.9% | -26.5% | Débil | |
| EBITDA Margin (Margen EBITDA) | -253.7%promedio 5A ≈-292.3% | ≈-292.3% | -18.9% | Débil | |
| Margen antes de impuestos (TTM) | -296.5%promedio 5A ≈-327.0% | ≈-327.0% | -14.3% | Débil | |
| Margen de Beneficio Neto (TTM) | -287.8%promedio 5A ≈-327.6% | ≈-327.6% | -10.7% | Débil | |
| ROA (TTM) | -24.1%promedio 5A ≈-43.9% | ≈-43.9% | -12.8% | Débil | |
| ROE (TTM) | -35.8%promedio 5A ≈-214.5% | ≈-214.5% | -21.0% | Débil | |
| ROIC | -155.8%promedio 5A ≈-139.8% | ≈-139.8% | -22.1% | Débil |
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
| Métrica | Tendencia a 5 años | NKTR | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Ratio corriente (MRQ) | 10.4promedio 5A ≈6.6 | ≈6.6 | 5.5 | Liquidez sólida | |
| Quick Ratio (Ratio Rápido) | 0.3promedio 5A ≈0.7 | ≈0.7 | 1.5 | Baja liquidez |
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
| Métrica | Tendencia a 5 años | NKTR | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Revenue YoY (Ingresos interanuales) | -43.9%promedio 5A ≈-16.0% | ≈-16.0% | · | · | |
| Revenue CAGR 3Y (Ingresos CAGR 3A) | -15.7%promedio 5A ≈-11.0% | ≈-11.0% | · | · | |
| Revenue CAGR 5Y (Ingresos CAGR 5A) | -18.4% | · | · | · |
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
| Métrica | Tendencia a 5 años | NKTR | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Asset Turnover (Rotación de Activos) | 0.2promedio 5A ≈0.2 | ≈0.2 | 0.5 | Débil | |
| Revenue / Employee (Ingresos / Empleado) | ≈$876.7K | · | · | · |
valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
8.3%
Próximo informe
Nov 04, 2026
| Período | Informe | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|---|
| 30 de junio de 2026 | Ago 13, 2026 | $-1.23 | $-2.02 | 39.2% |
| 31 de marzo de 2026 | May 7, 2026 | $-1.82 | $-1.63 | -11.9% |
| 31 de diciembre de 2025 | $-1.78 | $-2.52 | 29.5% | |
| 30 de septiembre de 2025 | $-1.87 | $-2.74 | 31.7% | |
| 30 de junio de 2025 | $-2.95 | $-3.10 | 4.7% | |
| 31 de marzo de 2025 | $-3.60 | $-2.51 | -43.2% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $55M | $98M | $90M | $92M | $102M | $153M | $115M | $1.19B | $308M | $165M | $231M | $201M | |
| Cost of Revenue | $0 | $31M | $34M | $22M | $25M | $19M | $21M | $24M | $31M | $30M | $34M | $29M | |
| R&D Expense | $117M | $121M | $114M | $218M | $400M | $409M | $435M | $400M | $268M | $204M | $183M | $148M | |
| SG&A Expense | $69M | $77M | $77M | $92M | $123M | $105M | $99M | $81M | $52M | $44M | $43M | $41M | |
| Operating Expenses | $195M | $204M | $354M | $468M | $548M | $578M | $555M | $505M | $367M | $278M | $260M | $217M | |
| Operating Income | $-140M | $-105M | $-264M | $-376M | $-446M | $-425M | $-440M | $688M | $-60M | $-113M | $-29M | $-16M | |
| Interest Expense | · | · | · | $0 | $0 | $7M | $21M | $22M | $22M | $22M | $18M | $18M | |
| Interest Income | $10M | $14M | $19M | $7M | $3M | · | · | · | · | · | · | · | |
| Other Non-op | $361.0K | $-390.0K | $-6M | $-116.0K | $-162.0K | $18M | $46M | $38M | $5M | $2M | $2M | $814.0K | |
| Pretax Income | $-164M | $-119M | $-276M | $-365M | $-523M | $-444M | $-440M | $683M | $-96M | $-153M | $-81M | $-54M | |
| Income Tax | $-138.0K | $-239.0K | $-200.0K | $3M | $557.0K | $493.0K | $613.0K | $1M | $616.0K | $876.0K | $506.0K | $-512.0K | |
| Net Income | $-164M | $-119M | $-276M | $-368M | $-524M | $-444M | $-441M | $681M | $-97M | $-154M | $-81M | $-54M | |
| EPS (Basic) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $4.02 | $-0.62 | $-1.10 | · | · | |
| EPS (Diluted) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $3.78 | $-0.62 | $-1.10 | · | · | |
| Shares (Basic) | 16,870,930 | 13,710,775 | 190,001,000 | 187,138,000 | 183,298,000 | 178,581,000 | 174,993,000 | 169,600,000 | 155,953,000 | 139,596,000 | · | · | |
| Shares (Diluted) | 16,870,930 | 13,710,775 | 190,001,000 | 187,138,000 | 183,298,000 | 178,581,000 | 174,993,000 | 180,119,000 | 155,953,000 | 139,596,000 | · | · | |
| EBITDA | $-140M | $-101M | $-257M | $-364M | $-433M | $-413M | $-429M | $697M | $-47M | $-113M | $-29M | · |
Balance general
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15M | $44M | $35M | $88M | $25M | $199M | $96M | $195M | $5M | $60M | $56M | $12M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $291M | $329M | $253M | $225M | |
| Receivables | · | $0 | $1M | $6M | $22M | $39M | $37M | $43M | $5M | $16M | $20M | $4M | |
| Inventory | $0 | $0 | $16M | $19M | $16M | $15M | $13M | $11M | $11M | $11M | $11M | $13M | |
| Other Current Assets | $21M | $6M | $10M | $16M | $23M | $22M | $15M | $21M | $8M | $10M | $10M | $9M | |
| Current Assets | $266M | $261M | $331M | $546M | $796M | $1.14B | $1.42B | $1.44B | $327M | $426M | $350M | $288M | |
| PP&E (Net) | $2M | $3M | $19M | $32M | $61M | $60M | $66M | $49M | $47M | $66M | $71M | $70M | |
| Accum. Depreciation | · | $16M | $87M | $125M | $148M | $138M | $128M | $121M | $115M | $111M | $103M | $94M | |
| Goodwill | · | · | $0 | $77M | $77M | $77M | $77M | $77M | $77M | $77M | $77M | $77M | |
| Other Non-current Assets | $14M | $5M | $5M | $2M | $3M | $1M | $344.0K | $4M | $994.0K | $817.0K | $754.0K | $7M | |
| Total Assets | $280M | $304M | $398M | $711M | $1.12B | $1.54B | $1.98B | $2.15B | $509M | $569M | $499M | $442M | |
| Accounts Payable | $11M | $12M | $10M | $13M | $10M | $22M | $19M | $6M | $5M | $3M | $2M | $3M | |
| Accrued Liabilities | $22M | $30M | $22M | $37M | · | · | · | · | · | · | · | $6M | |
| Current Liabilities | $54M | $61M | $51M | $68M | $85M | $116M | $354M | $82M | $56M | $72M | $61M | $64M | |
| Capital Leases | $65M | $83M | $99M | $113M | $126M | $136M | $143M | $0 | · | $2M | $1M | $4M | |
| Other Non-current Liabilities | $9M | $7M | $5M | $8M | $4M | $9M | $768.0K | $10M | $6M | $7M | $10M | $15M | |
| Total Liabilities | $191M | $243M | $267M | $344M | $438M | $461M | $572M | $433M | $421M | $481M | $492M | $405M | |
| Common Stock | $2.0K | $1.0K | $19.0K | $19.0K | $19.0K | $18.0K | $17.0K | $17.0K | $15.0K | $15.0K | $13.0K | $13.0K | |
| Retained Earnings | $-3.76B | $-3.60B | $-3.48B | $-3.20B | $-2.83B | $-2.31B | $-1.86B | $-1.42B | $-2.12B | $-2.02B | $-1.87B | $-1.79B | |
| Treasury Stock | · | $3M | $0 | · | · | · | · | · | · | · | · | · | |
| AOCI | $17.0K | $61.0K | $80.0K | $-7M | $-4M | $-2M | $-1M | $-6M | $-2M | $-2M | $-2M | $-2M | |
| Stockholders' Equity | $90M | $61M | $131M | $367M | $680M | $1.08B | $1.41B | $1.72B | $88M | $88M | $6M | $36M | |
| Liabilities + Equity | $280M | $304M | $398M | $711M | $1.12B | $1.54B | $1.98B | $2.15B | $509M | $569M | $499M | $442M | |
| Shares Outstanding | 20,378,832 | 12,385,001 | 12,757,984 | 188,560,000 | 185,468,000 | 180,091,000 | 176,505,000 | 173,530,000 | 159,524,000 | 153,212,000 | 135,289,000 | 131,216,000 |
Flujo de Efectivo
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $4M | $7M | $12M | $13M | $12M | $11M | $9M | $13M | $13M | $11M | $13M | |
| Stock-based Comp | · | · | · | · | · | · | · | · | · | · | · | $17M | |
| Deferred Tax | $64.0K | $-10.0K | $-140.0K | $3M | $-102.0K | $-36.0K | $-21.0K | $93.0K | $35.0K | $-115.0K | $-22.0K | $-31.0K | |
| Other Non-cash | · | $-61M | $77M | $49M | $98M | $119M | $101M | $28M | $4M | · | · | · | |
| Operating Cash Flow | $-209M | $-176M | $-193M | $-304M | $-413M | $-313M | $-329M | $718M | $-80M | $-117M | $-73M | $-142M | |
| CapEx | $171.0K | $1M | $865.0K | $6M | $15M | $7M | $26M | $14M | $10M | $6M | $11M | $10M | |
| Investing Cash Flow | $-1M | $143M | $140M | $366M | $203M | $496M | $207M | $-1.38B | $-29M | $-82M | · | · | |
| Stock Repurchased | $0 | $3M | $0 | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $0 | $-3M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $181M | $42M | $30.0K | $2M | $36M | $-80M | $23M | $852M | $54M | $204M | · | · | |
| Net Change in Cash | $-29M | $9M | $-53M | $63M | $-174M | $103M | $-99M | $190M | $-55M | $4M | $43M | $-27M | |
| Taxes Paid | $-195.0K | $76.0K | $3M | $272.0K | $325.0K | $539.0K | $555.0K | $618.0K | $556.0K | $757.0K | $860.0K | $964.0K | |
| Free Cash Flow | $-209M | $-177M | $-193M | $-310M | $-428M | $-321M | $-355M | $704M | $-90M | $-123M | $-84M | · | |
| Levered FCF | · | · | · | $-310M | $-428M | $-327M | $-376M | $682M | $-112M | $-146M | $-103M | · |
Rentabilidad
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% | -278.0% | -383.9% | 57.6% | -19.4% | -68.2% | -12.7% | · | |
| Net Margin | -297.1% | -120.9% | -306.3% | -400.0% | -514.0% | -290.6% | -384.5% | 57.1% | -31.4% | -92.8% | -35.2% | · | |
| Pretax Margin | -297.3% | -121.1% | -306.5% | -396.5% | -513.5% | -290.3% | -383.9% | 57.2% | -31.2% | -92.3% | -35.0% | · | |
| EBITDA Margin | -253.7% | -102.7% | -284.8% | -395.4% | -425.0% | -269.8% | -374.3% | 58.4% | -15.3% | -68.2% | -12.7% | · | |
| ROA | -56.2% | -33.9% | -49.8% | -40.3% | -39.5% | -25.3% | -21.3% | 51.2% | -17.9% | -28.8% | -17.2% | · | |
| ROE | -500.1% | -217.0% | -190.2% | -94.5% | -70.7% | -39.5% | -30.4% | 38.9% | -109.9% | -324.7% | -379.7% | · | |
| ROIC | -155.8% | -172.9% | -201.2% | -103.5% | -65.7% | -39.5% | -31.4% | 40.0% | -68.3% | -128.8% | -459.7% | · |
Liquidez y Solvencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.0 | 4.3 | 6.5 | 8.0 | 9.3 | 9.8 | 4.0 | 17.5 | 5.8 | 5.9 | 5.7 | · | |
| Quick Ratio | 0.3 | 0.7 | 0.7 | 1.4 | 0.6 | 2.1 | 0.4 | 2.9 | 5.4 | 5.6 | 5.4 | · | |
| Interest Coverage | · | · | · | · | · | -62.1 | -20.6 | 31.9 | -2.7 | -5.0 | -1.6 | · |
Eficiencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.9 | 0.6 | 0.3 | 0.5 | · | |
| Inventory Turnover | · | 3.8 | 1.9 | 1.2 | 1.6 | 1.4 | 1.8 | 2.2 | 2.8 | 2.7 | 2.8 | · | |
| Receivables Turnover | · | 163.4 | 25.1 | 6.5 | 3.3 | 4.0 | 2.9 | 49.5 | 29.7 | 9.3 | 19.6 | · |
Por Acción
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $4.41 | $0.33 | $0.68 | $1.94 | $3.66 | $5.98 | $7.96 | $9.90 | $0.55 | $0.58 | $0.05 | · | |
| Revenue / Share | $3.27 | $0.48 | $0.47 | $0.49 | $0.56 | $0.86 | $0.66 | $6.63 | · | · | · | · | |
| Cash Flow / Share | $-12.36 | $-0.85 | $-1.01 | $-1.62 | $-2.25 | $-1.75 | $-1.88 | $3.99 | · | · | · | · | |
| Cash / Share | $0.74 | $0.24 | $0.18 | $0.47 | $0.14 | $1.10 | $0.55 | $1.12 | $0.03 | $0.39 | $0.41 | · | |
| EPS (TTM) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $3.78 | $-0.62 | $-1.10 | $-0.61 | $-0.45 |
Tasas de Crecimiento
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -43.9% | 9.2% | -2.1% | -9.7% | -33.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -15.7% | -1.1% | -16.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -18.4% | · | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM)
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $55M | $98M | $90M | $92M | $102M | $153M | $115M | $1.19B | $308M | $165M | $231M | $201M | |
| Net Income TTM | $-164M | $-119M | $-276M | $-368M | $-524M | $-444M | $-441M | $681M | $-97M | $-154M | $-81M | $-54M | |
| Market Cap | $862M | $2.59B | $1.61B | $6.39B | $37.59B | $45.92B | $57.16B | $85.56B | $142.90B | $28.20B | $34.19B | · | |
| P/E | -4.3 | -1.6 | -5.8 | -17.2 | -70.9 | -102.4 | -128.5 | 130.4 | -1444.8 | -167.3 | -414.3 | -516.7 | |
| P/S | 15.6 | 26.3 | 17.8 | 69.4 | 368.8 | 300.3 | 498.7 | 71.7 | 464.4 | 170.5 | 148.2 | · | |
| P/B | 9.6 | 42.7 | 12.3 | 17.4 | 55.3 | 42.6 | 40.7 | 49.8 | 1627.1 | 320.0 | 5318.8 | · | |
| P / Tangible Book | 9.6 | 42.7 | 12.3 | 22.0 | 62.3 | 45.9 | · | · | · | · | · | · | |
| P / Cash Flow | -4.1 | -14.7 | -8.3 | -21.0 | -91.1 | -146.6 | -173.9 | 119.1 | -1777.1 | -241.0 | -467.9 | · | |
| P / FCF | -4.1 | -14.6 | -8.3 | -20.6 | -87.9 | -143.3 | -161.0 | 121.5 | -1586.2 | -228.5 | -405.7 | · | |
| Earnings Yield | -23.0% | -62.2% | -17.3% | -5.8% | -1.4% | -0.98% | -0.78% | 0.77% | -0.07% | -0.60% | -0.24% | -0.19% |
Estado de resultados
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $11M | $22M | $12M | $11M | $10M | $29M | $24M | $23M | $22M | $24M | $24M | $20M | $22M | $22M | $24M | |
| Cost of Revenue | · | · | $0 | $0 | $0 | $0 | $8M | $4M | $10M | $9M | $7M | $12M | $7M | $7M | $6M | $5M | |
| R&D Expense | $39M | $36M | $30M | $27M | $30M | $30M | $29M | $35M | $30M | $27M | $30M | $24M | $30M | $30M | $35M | $34M | |
| SG&A Expense | $13M | $13M | $11M | $16M | $17M | $24M | $17M | $19M | $21M | $20M | $17M | $21M | $18M | $21M | $22M | $23M | |
| Operating Expenses | $52M | $50M | $49M | $43M | $47M | $55M | $15M | $58M | $73M | $57M | $57M | $69M | $71M | $156M | $74M | $78M | |
| Operating Income | $-42M | $-39M | $-28M | $-32M | $-36M | $-45M | $14M | $-34M | $-50M | $-35M | $-34M | $-45M | $-51M | $-135M | $-52M | $-54M | |
| Interest Income | $9M | $4M | $3M | $3M | $2M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $5M | $4M | · | · | |
| Other Non-op | $-100.0K | $-336.0K | $-44.0K | $-121.0K | $260.0K | $266.0K | $-135.0K | $-120.0K | $-36.0K | $-99.0K | $-6M | $-335.0K | $736.0K | $-301.0K | $-4M | $2M | |
| Pretax Income | $-40M | $-43M | $-43M | $-35M | $-39M | $-46M | $7M | $-37M | $-52M | $-37M | $-42M | $-46M | $-51M | $-137M | $-57M | $-59M | |
| Income Tax | $2.0K | $64.0K | $31.0K | $-33.0K | $-188.0K | $52.0K | $-259.0K | $9.0K | $46.0K | $-35.0K | $-29.0K | $-61.0K | $-47.0K | $-63.0K | $3M | $-155.0K | |
| Net Income | $-41M | $-45M | $-36M | $-36M | $-42M | $-51M | $7M | $-37M | $-52M | $-37M | $-42M | $-46M | $-51M | $-137M | $-60M | $-59M | |
| EPS (Basic) | $-1.23 | $-1.82 | $-4.67 | $-1.87 | $-2.95 | $-3.62 | $-2.07 | $-2.66 | $-3.76 | $-0.19 | $-0.21 | $-0.24 | $-0.27 | $-0.73 | $-0.32 | $-0.31 | |
| EPS (Diluted) | $-1.23 | $-1.82 | $-4.67 | $-1.87 | $-2.95 | $-3.62 | $-2.07 | $-2.66 | $-3.76 | $-0.19 | $-0.21 | $-0.24 | $-0.27 | $-0.73 | $-0.32 | $-0.31 | |
| Shares (Basic) | 33,054,865 | 24,736,066 | · | 18,946,559 | 14,087,307 | 14,063,402 | · | 13,949,851 | 13,921,378 | 194,746,000 | · | 190,406,000 | 189,656,000 | 188,875,000 | · | 187,641,000 | |
| Shares (Diluted) | 33,054,865 | 24,736,066 | · | 18,946,559 | 14,087,307 | 14,063,402 | · | 13,949,851 | 13,921,378 | 194,746,000 | · | 190,406,000 | 189,656,000 | 188,875,000 | · | 187,641,000 | |
| EBITDA | $-42M | $-39M | · | $-32M | $-36M | $-45M | · | $-34M | $-50M | $-35M | · | $-45M | $-51M | $-135M | · | $-54M |
Balance general
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $39M | $150M | $15M | $41M | $43M | $39M | $44M | $30M | $28M | $49M | $35M | $65M | $51M | $77M | $88M | $106M | |
| Receivables | · | · | · | · | · | · | · | $0 | $1M | $4M | $1M | $2M | $1M | $3M | $6M | $12M | |
| Inventory | · | · | $0 | · | · | · | $0 | $0 | $14M | $16M | $16M | $15M | $21M | $20M | $19M | $19M | |
| Other Current Assets | $55M | $20M | $21M | $11M | $11M | $11M | $6M | $9M | $8M | $11M | $10M | $9M | $10M | $11M | $16M | $23M | |
| Current Assets | $739M | $589M | $266M | $281M | $187M | $230M | $261M | $286M | $295M | $320M | $331M | $399M | $441M | $491M | $546M | $599M | |
| PP&E (Net) | · | · | $2M | $3M | $3M | $3M | $3M | $4M | $15M | $17M | $19M | $20M | $23M | $27M | $32M | $37M | |
| Accum. Depreciation | · | · | · | · | · | · | · | $16M | $88M | · | $87M | $88M | $108M | $111M | $125M | · | |
| Goodwill | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $77M | $77M | |
| Other Non-current Assets | $17M | $11M | $6M | $5M | $5M | $5M | $5M | $5M | $4M | $5M | $5M | $5M | $2M | $1M | $2M | $2M | |
| Total Assets | $1.10B | $763M | $280M | $301M | $208M | $256M | $304M | $308M | $343M | $396M | $398M | $442M | $494M | $562M | $711M | $781M | |
| Accounts Payable | $25M | $10M | $11M | $16M | $14M | $18M | $12M | $9M | $6M | $9M | $10M | $3M | $3M | $4M | $13M | $5M | |
| Accrued Liabilities | $23M | $25M | $22M | $29M | $35M | $31M | $30M | $32M | $30M | $24M | $22M | $30M | $29M | $37M | $37M | · | |
| Current Liabilities | $71M | $58M | $54M | $66M | $71M | $71M | $61M | $68M | $57M | $52M | $51M | $52M | $51M | $60M | $68M | $84M | |
| Capital Leases | $56M | $61M | $65M | $70M | $74M | $78M | $83M | $87M | $91M | $95M | $99M | $102M | $106M | $109M | $113M | $116M | |
| Other Non-current Liabilities | $8M | $8M | $9M | $5M | $6M | $7M | $7M | $7M | $8M | $4M | $5M | $5M | $5M | $6M | $8M | $3M | |
| Total Liabilities | $192M | $187M | $191M | $216M | $232M | $243M | $243M | $259M | $264M | $269M | $267M | $283M | $297M | $321M | $344M | $369M | |
| Common Stock | $3.0K | $3.0K | $2.0K | $2.0K | $1.0K | $19.0K | $1.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | |
| Retained Earnings | $-3.85B | $-3.81B | $-3.76B | $-3.72B | $-3.69B | $-3.65B | $-3.60B | $-3.60B | $-3.57B | $-3.51B | $-3.48B | $-3.44B | $-3.39B | $-3.34B | $-3.20B | $-3.14B | |
| Treasury Stock | · | · | · | $0 | $3M | $3M | $3M | $3M | $3M | $3M | · | · | · | · | · | · | |
| AOCI | $-2M | $-1M | $17.0K | $56.0K | $-14.0K | $39.0K | $61.0K | $355.0K | $-494.0K | $-403.0K | $80.0K | $-6M | $-6M | $-6M | $-7M | $-8M | |
| Stockholders' Equity | $903M | $576M | $90M | $85M | $-24M | $14M | $61M | $49M | $80M | $127M | $131M | $159M | $197M | $241M | $367M | $412M | |
| Liabilities + Equity | $1.10B | $763M | $280M | $301M | $208M | $256M | $304M | $308M | $343M | $396M | $398M | $442M | $494M | $562M | $711M | $781M | |
| Shares Outstanding | 20,378,832 | 20,378,832 | 20,378,832 | 19,652,513 | 12,457,252 | 186,103,000 | 12,385,001 | 184,458,000 | 184,061,000 | 183,624,000 | 191,384,000 | 190,771,000 | 190,119,000 | 189,235,000 | 188,560,000 | 187,954,000 |
Flujo de Efectivo
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $156.0K | $151.0K | $190.0K | $196.0K | $214.0K | $426.0K | $332.0K | $993.0K | $1M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | |
| Deferred Tax | · | · | · | · | · | · | $2.0K | $-31.0K | $57.0K | $-38.0K | $2M | $-15.0K | $-27.0K | $-2M | $3M | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $17M | |
| Operating Cash Flow | $-76M | $-44M | $-65M | $-49M | $-46M | $-49M | $-46M | $-44M | $-38M | $-48M | $-47M | $-42M | $-52M | $-52M | $-58M | $-83M | |
| CapEx | $94.0K | $18.0K | $18.0K | $114.0K | $37.0K | $2.0K | $459.0K | $666.0K | $186.0K | $157.0K | $237.0K | $33.0K | $162.0K | $433.0K | $512.0K | $181.0K | |
| Investing Cash Flow | $-399M | $-351M | $372.0K | $-95M | $50M | $44M | $60M | $46M | $17M | $19M | $17M | $56M | $25M | $41M | $40M | $111M | |
| Stock Repurchased | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3M | $0 | $0 | $0 | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $-3M | · | · | · | · | · | · | |
| Financing Cash Flow | $365M | $530M | $39M | $142M | $211.0K | $7.0K | $83.0K | $13.0K | $19.0K | $42M | $12.0K | $0 | $18.0K | $0 | $103.0K | $0 | |
| Net Change in Cash | $-110M | $134M | $-26M | $-2M | $4M | $-5M | $14M | $2M | $-21M | $13M | $-30M | $14M | $-26M | $-11M | $-18M | $28M | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | · | $0 | $0 | · | · | $272.0K | $-85.0K | |
| Free Cash Flow | · | $-44M | · | · | · | $-49M | · | · | · | $-48M | · | · | · | $-52M | · | · |
Rentabilidad
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -417.9% | -359.6% | · | -268.6% | -324.2% | -425.8% | · | -142.4% | -211.9% | -163.7% | · | -185.8% | -246.8% | -623.8% | · | -229.9% | |
| Net Margin | -401.0% | -413.4% | · | -301.3% | -372.2% | -486.4% | · | -153.6% | -222.9% | -170.1% | · | -189.8% | -249.4% | -634.5% | · | -249.9% | |
| Pretax Margin | -397.8% | -396.7% | · | -297.0% | -352.5% | -443.3% | · | -153.6% | -222.7% | -170.2% | · | -190.1% | -249.6% | -634.8% | · | -250.6% | |
| EBITDA Margin | -417.9% | -359.6% | · | -268.6% | -324.2% | -425.8% | · | -142.4% | -211.9% | -163.7% | · | -185.8% | -246.8% | -623.8% | · | -229.9% | |
| ROA | -6.2% | -8.8% | · | -11.7% | -15.1% | -15.6% | · | -9.9% | -12.5% | -7.7% | · | -7.5% | -7.5% | -17.3% | · | -5.7% | |
| ROE | -9.2% | -15.2% | · | -53.0% | -150.0% | -72.5% | · | -35.6% | -37.9% | -20.0% | · | -16.0% | -15.6% | -32.3% | · | -9.7% | |
| ROIC | -4.7% | -6.8% | · | -37.2% | 148.9% | -324.5% | · | -70.3% | -62.5% | -27.9% | · | -28.1% | -25.7% | -55.9% | · | -13.1% |
Liquidez y Solvencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.4 | 10.2 | · | 4.2 | 2.6 | 3.2 | · | 4.2 | 5.1 | 6.1 | · | 7.7 | 8.7 | 8.2 | · | 7.1 | |
| Quick Ratio | 0.6 | 2.6 | · | 0.6 | 0.6 | 0.5 | · | 0.4 | 0.5 | 1.0 | · | 1.3 | 1.0 | 1.3 | · | 1.4 |
Eficiencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | · | · | · | · | · | · | · | 0.6 | 0.6 | 0.5 | · | 0.7 | 0.4 | 0.4 | · | 0.3 | |
| Receivables Turnover | · | · | · | · | · | · | · | 21.9 | 18.6 | 6.5 | · | 3.5 | 3.6 | 1.3 | · | 1.2 |
Por Acción
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $44.32 | $28.28 | · | $4.33 | $-1.94 | $0.07 | · | $0.27 | $0.43 | $0.69 | · | $0.84 | $1.04 | $1.27 | · | $2.19 | |
| Revenue / Share | $0.31 | $0.44 | · | $0.62 | $0.79 | $0.05 | · | $0.12 | $0.11 | $0.11 | · | $0.13 | $0.11 | $0.11 | · | $0.13 | |
| Cash Flow / Share | · | $-1.79 | · | · | · | $-0.23 | · | · | · | $-0.25 | · | · | · | $-0.27 | · | · | |
| Cash / Share | $1.93 | $7.34 | · | $2.09 | $3.45 | $0.21 | · | $0.16 | $0.15 | $0.26 | · | $0.34 | $0.27 | $0.41 | · | $0.56 | |
| EPS (TTM) | $-9.59 | $-11.31 | · | $-10.51 | $-11.30 | $-12.11 | · | $-6.82 | $-4.40 | $-0.91 | · | $-1.56 | $-1.63 | $-2.21 | · | $-2.44 |
Valoración (TTM)
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $55M | $56M | · | $63M | $75M | $87M | · | $93M | $93M | $90M | · | $88M | $88M | $89M | · | $95M | |
| Net Income TTM | $-157M | $-158M | · | $-121M | $-122M | $-133M | · | $-168M | $-177M | $-176M | · | $-294M | $-307M | $-415M | · | $-454M | |
| Market Cap | $1.42B | $1.47B | · | $1.12B | $322M | $1.90B | · | $3.60B | $3.42B | $2.56B | · | $1.72B | $1.65B | $1.99B | · | $9.02B | |
| P/E | -7.3 | -6.4 | · | -5.4 | -2.3 | -0.8 | · | -2.9 | -4.2 | -15.3 | · | -5.8 | -5.3 | -4.8 | · | -19.7 | |
| P/S | 26.1 | 26.4 | · | 17.9 | 4.3 | 21.8 | · | 38.6 | 36.8 | 28.4 | · | 19.5 | 18.9 | 22.4 | · | 94.9 | |
| P/B | 1.6 | 2.5 | · | 13.1 | -13.3 | 138.2 | · | 73.6 | 43.0 | 20.2 | · | 10.8 | 8.4 | 8.2 | · | 21.9 | |
| P / Tangible Book | 1.6 | 2.5 | · | 13.1 | · | 138.2 | · | 73.6 | 43.0 | 20.2 | · | 10.8 | 8.4 | 8.2 | · | 26.9 | |
| P / Cash Flow | · | -33.1 | · | · | · | -38.7 | · | · | · | -53.5 | · | · | · | -38.3 | · | · | |
| Earnings Yield | -13.7% | -15.7% | · | -18.5% | -43.7% | -118.7% | · | -35.0% | -23.7% | -6.5% | · | -17.3% | -18.7% | -21.1% | · | -5.1% |
Período más reciente a la izquierda · valores nulos mostrados como ·
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ingresos | $55M | $98M | $90M | $92M | $102M |
| Margen Operativo % | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% |
| Beneficio neto | $-164M | $-119M | $-276M | $-368M | $-524M |
| EPS Diluido | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ratio corriente | 5.0 | 4.3 | 6.5 | 8.0 | 9.3 |
| Ratio Rápido | 0.3 | 0.7 | 0.7 | 1.4 | 0.6 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flujo de caja libre | $-209M | $-177M | $-193M | $-310M | $-428M |
Propietarios institucionales (13F) 267 declarantes · $2.7B total · A fecha de 30 de septiembre de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Tenedores
267
Valor en tenencia
$2.7B
Nuevas posiciones
78
Posiciones cerradas
42
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 78 (+2 vs trimestre anterior) | 42 (+11 vs trimestre anterior) | 105 (+27 vs trimestre anterior) | 44 (-6 vs trimestre anterior) | +10.6M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| FMR LLC | $353 791 520 | 5 067 920 | 13,17% | Acciones |
| Two Seas Capital LP | $215 868 856 | 3 092 234 | 8,04% | Acciones |
| BlackRock, Inc. | $205 370 620 | 2 941 851 | 7,64% | Acciones |
| BVF INC/IL | $166 920 946 | 2 391 075 | 6,21% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $104 495 029 | 1 496 849 | 3,89% | Acciones |
| TWO SIGMA INVESTMENTS, LP | $83 911 899 | 1 202 004 | 3,12% | Acciones |
| Vestal Point Capital, LP | $69 810 000 | 1 000 000 | 2,60% | Acciones |
| MORGAN STANLEY | $65 381 263 | 936 560 | 2,43% | Acciones |
| STATE STREET CORP | $63 504 691 | 909 679 | 2,36% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $61 536 312 | 881 306 | 2,29% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $57 502 497 | 823 700 | 2,14% | Opción de compra |
| Prosight Management, LP | $56 546 100 | 810 000 | 2,10% | Acciones |
| ARMISTICE CAPITAL, LLC | $50 542 440 | 724 000 | 1,88% | Acciones |
| VANGUARD GROUP INC | $43 425 322 | 1 027 089 | 1,62% | Acciones |
| GILDER GAGNON HOWE & CO LLC | $41 946 944 | 600 873 | 1,56% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $33 377 557 | 478 120 | 1,24% | Acciones |
| BRAIDWELL LP | $33 063 203 | 473 617 | 1,23% | Acciones |
| Sofinnova Investments, Inc. | $32 933 775 | 471 763 | 1,23% | Acciones |
| Woodline Partners LP | $32 871 784 | 470 875 | 1,22% | Acciones |
| ORBIMED ADVISORS LLC | $32 485 804 | 465 346 | 1,21% | Acciones |
| UBS Group AG | $29 906 604 | 428 400 | 1,11% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $27 540 045 | 394 500 | 1,03% | Opción de venta |
| EMERALD ADVISERS, LLC | $27 236 930 | 390 158 | 1,01% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $24 331 577 | 348 540 | 0,91% | Acciones |
| DAFNA Capital Management LLC | $22 226 108 | 318 380 | 0,83% | Acciones |
| NORTHERN TRUST CORP | $21 538 548 | 308 531 | 0,80% | Acciones |
| Deep Track Capital, LP | $20 943 000 | 300 000 | 0,78% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $19 893 826 | 284 971 | 0,74% | Acciones |
| 22NW, LP | $19 624 638 | 281 115 | 0,73% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19 475 384 | 278 977 | 0,72% | Acciones |
| PRIMECAP MANAGEMENT CO/CA/ | $19 047 658 | 272 850 | 0,71% | Acciones |
| BARCLAYS PLC | $18 315 491 | 262 362 | 0,68% | Acciones |
| Nearwater Capital Markets, Ltd | $18 255 315 | 261 500 | 0,68% | Acciones |
| EMERALD MUTUAL FUND ADVISERS TRUST | $17 842 528 | 255 587 | 0,66% | Acciones |
| ADAR1 Capital Management, LLC | $17 046 485 | 244 184 | 0,63% | Acciones |
| Creek Drive Management Group LLC | $16 963 830 | 243 000 | 0,63% | Acciones |
| SEVEN GRAND MANAGERS, LLC | $16 754 400 | 240 000 | 0,62% | Acciones |
| DEUTSCHE BANK AG\ | $16 742 602 | 239 831 | 0,62% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $16 724 731 | 239 575 | 0,62% | Acciones |
| GOLDMAN SACHS GROUP INC | $15 950 887 | 228 490 | 0,59% | Acciones |
| NORGES BANK | $15 030 093 | 215 300 | 0,56% | Acciones |
| Bronte Capital Management Pty Ltd. | $13 852 678 | 198 434 | 0,52% | Acciones |
| TWO SIGMA ADVISERS, LP | $13 039 744 | 308 414 | 0,49% | Acciones |
| CITADEL ADVISORS LLC | $12 251 655 | 175 500 | 0,46% | Opción de venta |
| GREAT POINT PARTNERS LLC | $12 216 750 | 175 000 | 0,45% | Acciones |
| Caption Management, LLC | $11 944 491 | 171 100 | 0,44% | Opción de compra |
| MILLENNIUM MANAGEMENT LLC | $11 867 700 | 170 000 | 0,44% | Opción de compra |
| AMERIPRISE FINANCIAL INC | $11 584 330 | 165 941 | 0,43% | Acciones |
| CITADEL ADVISORS LLC | $11 434 878 | 163 800 | 0,43% | Opción de compra |
| CITADEL ADVISORS LLC | $11 151 938 | 159 747 | 0,42% | Acciones |
Activistas y propietarios del %+ 5 1 tenencia
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Nektar Therapeutics ( | 22 de agosto de 2005 | · | Presentación inicial | M&A / venta | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Informantes de la empresa 40 insiders · 20 directivos · 18 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Howard W Robin | President & CEO | 18 de agosto de 2026 S | 54 627 | 0 | 8 | $-1 424 905 |
| Jillian B. Thomsen | Chief Financial Officer | 16 de febrero de 2023 S | 313 497 | 0 | 0 | $0 |
| Gil M Labrucherie | SVP, COO & CFO | 16 de mayo de 2022 S | 312 905 | 0 | 0 | $0 |
| Timothy Harkness | SVP & Chief Financial Officer | 23 de agosto de 2007 A | · | 0 | 0 | $0 |
| Louis Drapeau | Sr. VP Finance, CFO | 14 de mayo de 2007 A | 6 000 | 0 | 0 | $0 |
| Milton J Harris | President of Nektar AL | 4 de marzo de 2004 S | 743 904 | 0 | 0 | $0 |
| John Nicholson | SVP & Chief Operating Officer | 16 de agosto de 2019 S | 162 759 | 0 | 0 | $0 |
| Bharat M Chowrira | Chief Operating Officer | 1 de febrero de 2010 A | · | 0 | 0 | $0 |
| Jonathan Zalevsky | Chief R&D Officer | 18 de agosto de 2026 S | 9 570 | 0 | 7 | $-974 184 |
| Mark Andrew Wilson | Chief Legal Officer | 21 de noviembre de 2025 A | 21 585 | 0 | 1 | $-34 196 |
| John Northcott | SVP & Chief Commercial Officer | 16 de mayo de 2022 S | 223 210 | 0 | 0 | $0 |
| Stephen K Doberstein | SVP & Chief Scientific Officer | 5 de septiembre de 2019 P | 107 668 | 0 | 0 | $0 |
| Maninder Hora | SVP Pharma Dev & Mfg Ops | 16 de mayo de 2019 S | 94 694 | 0 | 0 | $0 |
| Ivan P. Gergel | SVP & Chief Medical Officer | 15 de noviembre de 2017 A | 56 553 | 0 | 0 | $0 |
| Robert Medve | SVP & Chief Medical Officer | 5 de febrero de 2014 A | · | 0 | 0 | $0 |
| Rinko Ghosh | Chief Business Officer | 6 de febrero de 2013 A | 9 753 | 0 | 0 | $0 |
| Randall W Moreadith | SVP Drug Development | 23 de febrero de 2009 A | · | 0 | 0 | $0 |
| John Stuart Patton | Chief Scientific Officer | 14 de noviembre de 2008 M | 313 880 | 0 | 0 | $0 |
| Nevan C Elam | SVP & Head of Pulmonary Bus | 25 de febrero de 2008 A | 1 400 | 0 | 0 | $0 |
| David Johnston | SVP, Research & Development | 14 de mayo de 2007 D | 6 600 | 0 | 0 | $0 |
| Diana Brainard | Consejero | 23 de septiembre de 2026 A | 3 904 | 0 | 0 | $0 |
| Jeffrey Robert Ajer | Consejero | 23 de septiembre de 2026 A | 4 277 | 0 | 0 | $0 |
| Robert Chess | Consejero | 23 de septiembre de 2026 A | 19 019 | 0 | 0 | $0 |
| Scott R Greer | Consejero | 23 de septiembre de 2026 A | 22 239 | 0 | 0 | $0 |
| Roy A Whitfield | Consejero | 23 de septiembre de 2026 A | 16 417 | 0 | 0 | $0 |
| Myriam Curet | Consejero | 19 de septiembre de 2023 A | 27 418 | 0 | 0 | $0 |
| Karin Eastham | Consejero | 16 de septiembre de 2022 A | 23 233 | 0 | 0 | $0 |
| Lutz Lingnau | Consejero | 22 de septiembre de 2020 A | 35 800 | 0 | 0 | $0 |
| Christopher A Kuebler | Consejero | 27 de septiembre de 2018 A | 45 250 | 0 | 0 | $0 |
| Dennis L Winger | Consejero | 21 de agosto de 2018 M | 42 750 | 0 | 0 | $0 |
| Joseph J Krivulka | Consejero | 19 de septiembre de 2017 A | 82 000 | 0 | 0 | $0 |
| Susan Wang | Consejero | 20 de noviembre de 2015 M | 20 000 | 0 | 0 | $0 |
| BROWN MICHAEL A/CA | Consejero | 15 de septiembre de 2009 A | 10 000 | 0 | 0 | $0 |
| Hoyoung Huh | Consejero | 2 de diciembre de 2008 A | · | 0 | 0 | $0 |
| Irwin Lerner | Consejero | 2 de diciembre de 2008 A | 10 000 | 0 | 0 | $0 |
| James B Glavin | Consejero | 4 de septiembre de 2003 A | · | 0 | 0 | $0 |
| Masuoka K. Lorianne | · | 8 de febrero de 2011 A | · | 0 | 0 | $0 |
| Ajit Gill | President & CEO | 23 de marzo de 2006 S | 87 991 | 0 | 0 | $0 |
| Ajay Bansal | · | 10 de marzo de 2006 S | 5 166 | 0 | 0 | $0 |
| Melvin Perelman | · | 2 de septiembre de 2004 A | · | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Propiedad de ETFs Mantenido por 26 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| SPIT · RBB Fund, Inc. | 2,05% | 9 695 NS | 31 de julio de 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1,42% | 4 138 NS | 31 de julio de 2026 | N-PORT |
| BBC · ETFis Series Trust I | 0,80% | 5 234 NS | 31 de julio de 2026 | N-PORT |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,62% | 53 474 SH | 2 de octubre de 2026 | Diario |
| IHE · iShares Trust | 0,55% | 125 055 SH | 11 de septiembre de 2026 | Diario |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,34% | 1 670 SH | 2 de octubre de 2026 | Diario |
| IWO · iShares Trust | 0,14% | 289 334 SH | 11 de septiembre de 2026 | Diario |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,13% | 33 135 SH | 19 de agosto de 2026 | Diario |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,08% | 7 900 NS | 31 de julio de 2026 | N-PORT |
| IWM · iShares Trust | 0,08% | 879 755 SH | 11 de septiembre de 2026 | Diario |
| RSSL · Global X Funds | 0,08% | 16 502 NS | 31 de julio de 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,07% | 198 365 SH | 19 de agosto de 2026 | Diario |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,07% | 36 763 SH | 2 de octubre de 2026 | Diario |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 14 592 NS | 31 de julio de 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 387 471 SH | 19 de agosto de 2026 | Diario |
| VHT · VANGUARD WORLD FUND | 0,03% | 92 340 SH | 19 de agosto de 2026 | Diario |
| WSML · iShares Trust | 0,02% | 1 906 SH | 11 de septiembre de 2026 | Diario |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 3 096 SH | 19 de agosto de 2026 | Diario |
| ITOT · iShares Trust | 0,00% | 48 120 SH | 11 de septiembre de 2026 | Diario |
| IWV · iShares Trust | 0,00% | 9 239 SH | 11 de septiembre de 2026 | Diario |
| TILT · FlexShares Trust | 0,00% | 810 NS | 31 de julio de 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1 075 430 SH | 19 de agosto de 2026 | Diario |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2 837 SH | 19 de agosto de 2026 | Diario |
| IWN · iShares Trust | · | 32 591 SH | 11 de septiembre de 2026 | Diario |
| ISCB · iShares Trust | · | 1 294 SH | 11 de septiembre de 2026 | Diario |
| ISCV · iShares Trust | · | 6 414 SH | 11 de septiembre de 2026 | Diario |
NKTR Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
calificación · 18 analistas
COMPRA
Objetivo mediano
$150.50
+245,3%
7 38,9%
Compra fuerte
8 44,4%
Compra
3 16,7%
Mantener
0 0,0%
Venta
0 0,0%
Venta fuerte
Precio objetivo a 12 meses
10 analistas · 2026-09-27Objetivo medio $141.40 +224,5%
← Por Debajo de Todos los Objetivos
Precio Actual $43.58
Mín$50.00
Media$141.40
Máx$192.00
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| NKTR | $862M | -4.3 | -43.9% | -297.1% | -500.1% | · |
| ANIP | $1.78B | 23.8 | 43.8% | 8.9% | 16.6% | · |
| ETON | $457M | · | 104.9% | -5.8% | -18.4% | 53.5% |
| RAPP | $1.45B | -10.6 | · | · | -29.8% | · |
| OCUL | $2.62B | -8.5 | -18.5% | -511.9% | -55.4% | · |
| PAHC | · | 12.9 | 17.1% | 6.6% | 29.7% | 33.8% |
| INVA | · | 6.1 | 14.7% | · | · | · |
| MAZE | $2.04B | -13.6 | · | · | -598.9% | · |
| XERS | $1.30B | · | 43.7% | 0.19% | -19.7% | · |
| KARD | · | · | · | · | · | · |
| OMER | $1.23B | -343.6 | · | · | 1.9% | · |
Últimas noticias Noticias recientes que mencionan a esta empresa
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Fuente: SEC 10-Q presentada el Ago 14, 2026